As of 2024-12-11, the Intrinsic Value of Creo Medical Group PLC (CREO.L) is
658.10 GBP. This CREO.L valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y).
With the current market price of 14.50 GBP, the upside of Creo Medical Group PLC is
4,438.60%.
The range of the Intrinsic Value is 249.57 - 1,121.41 GBP
658.10 GBP
Intrinsic Value
CREO.L Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(14,654.82) - (2,877.61) |
(4,725.65) |
-32690.7% |
| DCF (Growth 10y) |
(5,433.46) - (28,130.52) |
(9,006.74) |
-62215.5% |
| DCF (EBITDA 5y) |
249.57 - 1,121.41 |
658.10 |
4438.6% |
| DCF (EBITDA 10y) |
848.98 - 4,059.00 |
2,263.94 |
15513.4% |
| Fair Value |
-26.95 - -26.95 |
-26.95 |
-285.84% |
| P/E |
(133.65) - (123.95) |
(125.57) |
-966.0% |
| EV/EBITDA |
(38.06) - 264.86 |
96.71 |
567.0% |
| EPV |
(68.58) - (100.05) |
(84.31) |
-681.5% |
| DDM - Stable |
(61.14) - (436.53) |
(248.83) |
-1816.1% |
| DDM - Multi |
(150.22) - (852.51) |
(257.37) |
-1875.0% |
CREO.L Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
60.27 |
| Beta |
0.72 |
| Outstanding shares (mil) |
4.16 |
| Enterprise Value (mil) |
64.67 |
| Market risk premium |
5.98% |
| Cost of Equity |
7.64% |
| Cost of Debt |
7.77% |
| WACC |
7.53% |